Non-muscle Invasive Bladder Cancer Market Trends

1. DelveInsight Business Research USA: 304 S. Jones Blvd #2432, Las Vegas NV 89107 India: Sector-7, Dwarka, New Delhi-110077, India USA: +1(919)321-6187 India: +91-11-45689769,+91-9650213330

3. What is Non-muscle Invasive Bladder Cancer & It's Market? DelveInsight’s ‘NMIBC Market Insights, Epidemiology and Market Forecast–2030’ report delivers an in-depth understanding of the NMIBC, historical and forecasted epidemiology as well as the NMIBC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

4. The NMIBC treatment market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM NMIBC market size from 2017 to 2030.The report also covers current NMIBC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

5. Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. The bladder muscle is not involved. NMIBC, formerly known as superficial bladder cancer, is a common, heterogeneous disease associated with high rates of recurrence and that often requires lifelong surveillance. The bladder is a vessel that stores urine produced by the kidneys before excretion. The bladder itself is made up of several tissue layers. The first two layers include the urothelial and the lamina propria layers. The urothelial or mucosal layer makes contact with the bladder contents, while the lamina propria, or submucosal layer, and connects the urothelial layer to the underlying smooth muscle. Bladder cancer is a common malignancy arising from the urothelial cells and is responsible for considerable morbidity and mortality.

6. The most common symptom of bladder cancer is hematuria, which occurs in 80–90% of patients. Approximately 70% of newly diagnosed cases of bladder cancer are NMIBC, meaning that they are confined to the urothelial and lamina propria layers of the bladder. Among NMIBCs, around 70% present as Ta lesions (papillary tumor confined to the urothelium), 20% as T1 lesions (tumor invades the lamina propria), and 10% as carcinoma in situ (CIS) (flat, high-grade tumor confined to the urothelial layer). Moreover, Keytruda (pembrolizumab) is the only approved drug for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

7. Intravesical BCG is commonly used as an adjuvant treatment after TURBT for intermediate-high-risk NMIBC. Local and systemic side effects are common with BCG and can lead to discontinuation of therapy in up to 20% of patients. However, up to 50% of patients fail BCG, significantly increasing the risk of progression and death. Patients who have failed BCG therapy require radical cystectomy with urinary diversion or chemotherapy and radiation, both of which are associated with considerable morbidity. Read More- NMIBC Market Drugs

8. Thank you